SCHEMBL978430

SCHEMBL978430

CCOC(=O)c1cc(F)cc(NS(=O)(=O)CC2CN(C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)C2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.38
LMNA P02545 1/20 0.38
S1PR1 P21453 1/20 0.37
S1PR3 Q99500 1/20 0.37
ACHE P22303 3/20 0.37
BCHE P06276 2/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
MAPT P10636 3/20 0.37
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
GPR119 Q8TDV5 2/20 0.36
SLC6A9 P48067 1/20 0.36
SCN9A Q15858 2/20 0.35
SREBF1 P36956 1/20 0.35
NR1H2 P55055 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL977022 0.92 SLC6A9 (0.37) HPGDLMNAMAPTSLC6A9SCN9A
SCHEMBL977039 0.91 NHERF1 (0.40) HPGDLMNAGAAMAPTCA1
SCHEMBL974855 0.90 HPGD (0.38) HPGDLMNAMAPTCA1CA2
SCHEMBL976538 0.90 BCHE (0.38) HPGDLMNAACHEBCHEMAPT
SCHEMBL977049 0.89 SCN9A (0.39) HPGDCA1CA2SCN9A
SCHEMBL977289 0.88 CA12 (0.37) LMNAMAPTCA1CA2CA12
SCHEMBL977293 0.88 CA12 (0.37) LMNAMAPTCA1CA2CA12
SCHEMBL974202 0.87 WDR5 (0.41) LMNASLC6A9SCN9A
SCHEMBL979322 0.85 TCF4 (0.37) HPGDLMNAGAASLC6A9SCN9A
SCHEMBL975372 0.85 KDM4E (0.41) HPGDLMNAMAPTCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130237513-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI (FR) 2013-09-12 US disclosed
US-8445478-B2 Azetidine derivatives, their preparation and their application in therapy SANOFI (FR) 2013-05-21 US disclosed
US-20110009377-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI-AVENTIS (FR) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237513-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY QDPR, AZI2, ADRA1B HPGD 1612/4885LMNA 3943/4885S1PR1 545/4885
US-20110009377-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY QDPR, AZI2, ADRA1B HPGD 1612/4885LMNA 3943/4885S1PR1 545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.